- Home
- UHS vs QGEN Comparison
UHS vs QGEN Comparison
Compare UHS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHS | QGEN |
|---|---|---|
| Founded | 1978 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | UHS | QGEN |
|---|---|---|
| Price | $231.02 | $47.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $232.58 | $50.68 |
| AVG Volume (30 Days) | 663.8K | ★ 1.2M |
| Earning Date | 10-27-2025 | 11-04-2025 |
| Dividend Yield | 0.35% | ★ 3.21% |
| EPS Growth | 39.76 | ★ 331.20 |
| EPS | ★ 21.01 | 1.84 |
| Revenue | ★ $16,992,503,000.00 | $2,070,781,000.00 |
| Revenue This Year | $10.93 | $7.12 |
| Revenue Next Year | $4.96 | $6.13 |
| P/E Ratio | ★ $11.00 | $25.56 |
| Revenue Growth | ★ 10.21 | 5.32 |
| 52 Week Low | $152.33 | $37.63 |
| 52 Week High | $246.33 | $51.88 |
Technical Indicators
Market Signals| Indicator | UHS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 55.46 |
| Support Level | $228.00 | $46.39 |
| Resistance Level | $246.33 | $48.13 |
| Average True Range (ATR) | 5.99 | 0.67 |
| MACD | -1.35 | 0.18 |
| Stochastic Oscillator | 37.86 | 68.53 |
Price Performance
Historical ComparisonAbout UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).